Deargen and Serengen Partner to Accelerate Drug Discovery

Get ready to take hit ID in drug discovery to the next level! Serengen and Deargen have partnered up to integrate their DEL and AI platforms for a faster, more affordable and effective drug discovery.

DORTMUND, Germany:

Serengen and Deargen are excited to announce their collaboration to accelerate the drug discovery process. This strategic partnership brings together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s leading AI-driven drug discovery platform, known as DearDTI.

The world of drug discovery is about to get a major boost as two cutting-edge technologies join forces. The integration of Serengen’s unrivalled DEL technology with Deargen’s leading AI platform offers many advantages over traditional drug discovery methods, including cost savings and faster lead generation while increasing effectiveness. This powerful collaboration will usher in a new era of drug discovery that will revolutionise current processes.

“By integrating Deargen’s DearDTI with Serengen’s DEL technology, the hit discovery process gains a boost in diversity and accuracy,” said KilSoo Kang, CEO of Deargen. “This collaboration aims to bring enhanced efficiency and success rates in drug development, creating a synergistic effect. Both companies share the common goal of offering valuable insights to their clients, seeking innovative and efficient drug discovery solutions, and are committed to fostering ongoing collaboration between Serengen and Deargen.

“Serengen’s slogan is ‘Serendipity by Design’ because our technology enables a unique DEL design,” added Thorsten Genski, CEO of Serengen. “Serendipity favours the prepared mind, as history has shown time and again. Nowadays, Artificial Intelligence is capable of analysis and prediction beyond the capabilities of a trained mind. We are excited to work with Deargen because the combination of DEL technology with Artificial Intelligence is the future. It will elevate our DEL design and data analysis to the highest level.”

About Deargen Inc.: Deargen is an AI-first pharmatech company dedicated to integrating AI technology and biological data together to maximise the discovery of new medicines. Its proprietary Drug-Target Interaction (DTI) platform predicts the binding affinity and activity score between a drug-target pair. This technology unlocks substantial potential in pursuing undruggable targets, thus enhancing the accessibility and cost-effectiveness of the hit discovery process.

About Serengen GmbH: Serengen’s mission is to accelerate hit identification and make serendipitous discovery accessible to everyone. Its services include the screening of DELs tailored to individual projects. The company’s technology overcomes the limitations of traditional DEL synthesis, allowing for a different design and approach.


Serengen GmbH
Thorsten Genski
Chief Executive Officer
+49 231 999 50 902

Deargen Inc.
MinJi Shin
Global Business Team Manager
+82 10 9258 2263